---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-107276"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:55:15.628593+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics FY2025 net loss $21.2M; cash $46.8M, ALS trial enrolling

## Summary
- Cash and cash equivalents $46.8M at Dec 31, 2025; collaboration revenue $7.9M (up from $3.6M).
- R&D expenses $16.7M (up $4.8M); net loss $21.2M vs $14.9M in FY2024.
- COYA 302 ALSTARS Phase 2 trial actively enrolling across ~25 sites in US and Canada.
- FDA accepted IND for COYA 302 in frontotemporal dementia (FTD); Phase 2a expected 2H2026.
- Completed $23M public offering and $11.1M private placement; cash runway into 2H2027.

## SEC filing metadata
- accession: 0001193125-26-107276
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312526107276/0001193125-26-107276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312526107276/coya-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-107276
- JSON: https://secwatch.observer/filing/0001193125-26-107276.json
- Plain text: https://secwatch.observer/filing/0001193125-26-107276.txt

## Key facts
- Earnings Releases
  Coya Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $21.2 million.
  - Period: the year ended December 31, 2025
  - Net income: $21.2 million
  - Result: reported results
  source text: Net loss was $21.2 million for the year ended December 31, 2025, compared to net loss of $14.9 million for the year ended December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312526107276/0001193125-26-107276-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.